Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men
International Journal of Cancer , Volume 138 - Issue 10 p. 2522- 2528
A significant proportion of screen-detected men with prostate cancer is likely to be overtreated, especially in older age groups. We aim to find which groups of screen-detected older men (65+) benefit the most from Immediate Radical Treatment or Active Surveillance (AS) for prostate cancer, depending on age, screening history, health status and prostate cancer stage at detection. We used a microsimulation model (MISCAN) of the natural history of prostate cancer based on ERSPC data. Individual life histories are simulated with US comorbidity lifetables based on a random sample of MEDICARE data. Different screening histories are simulated and we count outcomes for men screen-detected from ages 66 to 72. For immediately treated men with low-risk disease (≤ T2a, Gleason 6) the probability of overtreatment ranges from 61% to 86% decreasing to between 37 and 46%, if they are assigned to AS. For intermediate risk men (≤T2, Gleason 3 + 4) overtreatment ranges from 23 to 60%, which reduces to between 16 and 31% for AS. For high risk men (T3, or ≥ Gleason 4 + 3), overtreatment ranges from 11 to 51%. The disease stage at screen-detection is a critical risk factor for overtreatment. For low risk men, AS seems to significantly reduce overtreatment at a modest cost. For intermediate risk men, the decision between immediate treatment or AS depends on age and comorbidity status. Men screen-detected in a high risk disease stage may benefit from immediate treatment even beyond age 69.
|comorbidity, microsimulation model, overtreatment, prostate cancer screening|
|International Journal of Cancer|
|Organisation||Department of Public Health|
de Carvalho Delgado Marques, T.M, Heijnsdijk, E.A.M, & de Koning, H.J. (2016). Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men. International Journal of Cancer, 138(10), 2522–2528. doi:10.1002/ijc.29976